Advertisement

Topics

M7824 (Anti-PD-L1/TGF-Beta TRAP) in a Window Setting in Patients With Stage II-III HER2/Neu Positive (HER2+) Breast Cancer (BC)

2018-08-12 17:25:12 | BioPortfolio

Published on BioPortfolio: 2018-08-12T17:25:12-0400

Clinical Trials [6382 Associated Clinical Trials listed on BioPortfolio]

M7824 and Eribulin Mesylate in Treating Participants With Metastatic Triple Negative Breast Cancer

This phase Ib trial studies best dose and side effects of eribulin mesylate when given together with anti-PD-L1/TGFbetaRII fusion protein M7824 (M7824) in treating participants with triple...

RACHEL1: Radiation and CHEckpoint bLockade Trial in Patients With Metastatic Hormone Receptor Positive, HER2 Negative Breast Cancer

The goal of this clinical research study is to find the highest tolerable dose of M7824 (MSB0011359C) that can be given with radiation therapy to patients with estrogen and/or progesterone...

Immune Response in Patients Who Have Undergone Vaccine Therapy for Stage III or Stage IV Breast Cancer That Overexpresses HER2

RATIONALE: Studying the immune response to a vaccine made from HER2/neu protein may help doctors plan better treatment for patients with breast cancer that overexpresses HER2. PURPOSE: Th...

M7824 in Consensus Molecular Subtype 4, Treatment-Refractory Metastatic Colorectal Cancer

The goal of this clinical research study is to learn about the safety of giving M7824 to patients with colorectal cancer. Researchers also want to learn if the study drug can help to contr...

MVA-BN®-HER2 Vaccine in Locally Advanced & Advanced HER2+ Breast Cancer (Gene Transfer Protocol)

Primary Objectives: To evaluate the safety of MVA-BN-HER2 in women with HER-2-positive breast cancer. Secondary Objectives: To evaluate the ability of MVA-BN-HER2 to generate humo...

PubMed Articles [37998 Associated PubMed Articles listed on BioPortfolio]

Prediction of postoperative disease-free survival and brain metastasis for HER2-positive breast cancer patients treated with neoadjuvant chemotherapy plus trastuzumab using a machine learning algorithm.

This study aimed to develop mathematical tools to predict the likelihood of recurrence after neoadjuvant chemotherapy (NAC) plus trastuzumab in patients with human epidermal growth factor receptor 2 (...

Impact of Neoadjuvant Chemotherapy on Breast Cancer Subtype: Does Subtype Change and, if so, How? : IHC Profile and Neoadjuvant Chemotherapy.

Breast cancer subtype, as determined by the expression of estrogen receptor (ER) and progesterone receptor (PR), together defined as hormone receptor (HR) status, and the HER2/neu receptor (HER2), is ...

Neoadjuvant Pertuzumab-containing Regimens Improve Pathologic Complete Response Rates in Stage II to III HER-2/neu-positive Breast Cancer: A Retrospective, Single Institution Experience.

Several human epidermal growth factor 2 (HER2)-targeted regimens are used to treat HER2-positive (HER2) breast cancer (BC). The goal of this study was to retrospectively determine the pathologic compl...

Safety and Efficacy of Panitumumab Plus Neoadjuvant Chemotherapy in Patients With Primary HER2-Negative Inflammatory Breast Cancer.

Combining conventional chemotherapy with targeted therapy has been proposed to improve the pathologic complete response (pCR) rate in patients with inflammatory breast cancer (IBC). Epidermal growth f...

Gene expression assay and Watson for Oncology for optimization of treatment in ER-positive, HER2-negative breast cancer.

Personalized treatment for cancer patients is a hot topic of debate, particularly the decision to initiate chemotherapy in patients with Estrogen receptor (ER)-positive, HER2-negative tumors in the ea...

Medical and Biotech [MESH] Definitions

A humanized monoclonal antibody against the ERBB-2 RECEPTOR (HER2). As an ANTINEOPLASTIC AGENT, it is used to treat BREAST CANCER where HER2 is overexpressed.

Abnormal accumulation of lymph in the arm, shoulder and breast area associated with surgical or radiation breast cancer treatments (e.g., MASTECTOMY).

Carbohydrate antigen elevated in patients with tumors of the breast, ovary, lung, and prostate as well as other disorders. The mucin is expressed normally by most glandular epithelia but shows particularly increased expression in the breast at lactation and in malignancy. It is thus an established serum marker for breast cancer.

Metastatic breast cancer characterized by EDEMA and ERYTHEMA of the affected breast due to LYMPHATIC METASTASIS and eventual obstruction of LYMPHATIC VESSELS by the cancer cells.

The phosphoprotein encoded by the BRCA1 gene (GENE, BRCA1). In normal cells the BRCA1 protein is localized in the nucleus, whereas in the majority of breast cancer cell lines and in malignant pleural effusions from breast cancer patients, it is localized mainly in the cytoplasm. (Science 1995;270(5237):713,789-91)

More From BioPortfolio on "M7824 (Anti-PD-L1/TGF-Beta TRAP) in a Window Setting in Patients With Stage II-III HER2/Neu Positive (HER2+) Breast Cancer (BC)"

Advertisement
Quick Search
Advertisement
Advertisement

 

Searches Linking to this Trial